Smith+Nephew launches industry-first OR3O™ Dual Mobility System utilising unique OXINIUM™ DH metal alloy for use in primary and revision hip arthroplasty

OXINIUM Technology is the first advanced bearing material available to support modular dual mobility throughout the entire offering

Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty. Compared with traditional solutions, dual mobility implants have a small diameter femoral head that locks into a larger polyethylene insert - increasing stability and offering improved range of motion.¹

Since its introduction in 2010, the dual mobility segment has grown rapidly, and today 9% of primary hip arthroplasty procedures and 28% of revisions in the American Joint Registry utilized a dual mobility device.²

OR3O incorporates Smith+Nephew's latest advanced bearing surface, OXINIUM DH (Diffusion Hardened), for its liner as well as its proprietary VERILAST™ Technology for its femoral head and polyethylene inserts. OXINIUM Technology has been shown to deliver significant reductions in wear compared to Cobalt Chrome (CoCr), the material used in most competitive products.³

"The OR3O Dual Mobility System is truly a fourth generation dual mobility offering by introducing OXINIUM technologies. This is a solution that allows patients to get back to their lives by providing stability and offers unique advantages compared to other systems," said Stephen Duncan, MD an orthopedic surgeon at the University of Kentucky.

"Our new OR3O Dual Mobility System is a groundbreaking product that offers technology not available in competitive systems," said Skip Kiil, President of Orthopaedics at Smith+Nephew. "The proven success of our VERILAST Technology and OXINIUM DH bearing surface set OR3O apart as a game changing solution in the hip arthroplasty market."

OXINIUM DH is the newest addition to Smith+Nephew's OXINIUM platform and increases the depth of hardening through a patented technology process. It is designed specifically to address hip arthroplasty needs.

Smith+Nephew's OR3O Dual Mobility System is available in the United States for both primary and revision applications and offers cross-compatibility with the R3 and REDAPT acetabular systems.

Enquiries

Media

David Snyder
+1 978-749-1440
Smith+Nephew

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 16,000+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.9 billion in 2018. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

^{Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.}

^{◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.}